GlassScriptPhysician profile
Robert Alexander Davis
NPI 1932234523
$216,516.85
in general payments reported to CMS, 2019-2025
23 companies · $51K in 2025
The $51K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,323 · 2020: $12K · 2021: $23K · 2022: $39K · 2023: $41K · 2024: $47K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Travel and Lodging: $32K · Food and Beverage: $8,491 · Consulting Fee: $5,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,175.00 |
| Travel and Lodging | $32,486.98 |
| Food and Beverage | $8,490.81 |
| Consulting Fee | $5,975.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $210,421.09 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $2,562.19 | 2019-2025 | Dailies Total1, Precision 1, Dailies Aqua Comfort Plus |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,011.71 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $462.84 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $450.43 | 2022-2025 | Miebo, Infuse Multifocal, Xiidra |
| Abbvie INC. | $278.39 | 2023-2025 | Lumigan, Alphagan P, Vuity |
| New World Medical,INC. | $224.24 | 2023-2025 | Kahook Dual Blade, Streamline, Via360 |
| Coopervision INC. | $177.66 | 2019-2024 | Myday Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $164.01 | 2020-2022 | |
| Allergan, INC. | $152.14 | 2019-2022 | |
| Horizon Therapeutics Plc | $120.89 | 2022 | |
| Biotissue Holdings INC. | $102.34 | 2025 | |
| Maculogix, INC. | $65.02 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $60.90 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $43.16 | 2024-2025 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $35.12 | 2021-2022 | |
| Visioneering Technologies, INC. | $34.18 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.65 | 2020-2022 | |
| Dompe US, INC. | $29.60 | 2025 | Oxervate |
| Optos, INC. | $28.41 | 2019-2020 | |
| Harrow Eye, LLC | $26.00 | 2025 | Vevye |
| Amgen INC. | $19.26 | 2024 | Tepezza |
| Shire North American Group INC | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.